Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Cue Biopharma And 2 Other Stocks Under $3 Insiders Are Buying

Published 30/08/2023, 12:49
© Reuters.  Cue Biopharma And 2 Other Stocks Under $3 Insiders Are Buying
US500
-
KINS
-
CUE
-

Benzinga - by Lisa Levin, Benzinga Editor.

The Dow Jones closed higher by close to 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Kingstone Companies

  • The Trade: Kingstone Companies, Inc. (NASDAQ: KINS) Chief Operating Officer Meryl S Golden acquired a total of 5,811 shares an average price of $1.98. To acquire these shares, it cost around $11,507.
  • What’s Happening: Kingstone Companies posted a wider-than-expected quarterly loss.
  • What Kingstone Companies Does: Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company.
International Isotopes
  • The Trade: International Isotopes Inc. (OTC: INIS) President Shahe Bagerdjian acquired a total of 3,950 shares at an average price of $0.05. The insider spent around $197.50.
  • What’s Happening: The company said revenue for the six months ended June 30, 2023, was $6,201,700, up from $5,242,249 for the year-ago period.
  • What International Isotopes Does: International Isotopes Inc manufactures a full range of nuclear medicine calibration and reference standards, cobalt teletherapy sources, and other sealed sources.
Cue Biopharma
  • The Trade: Cue Biopharma, Inc. (NASDAQ: CUE) President and CSO Anish Suri acquired a total of 4,000 shares at an average price of $2.76. To acquire these shares, it cost around $11,040.
  • What’s Happening: Cue Biopharma posted upbeat quarterly results.
  • What Cue Biopharma Does: Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders.

Check This Out: Investor Sentiment Improves After S&P 500 Closes Sharply Higher

Don’t forget to check out our premarket coverage here

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.